– USA, MA – Ratio Therapeutics Inc., an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced the appointment of Former U.S. Senator Mo Cowan to its Board of Directors, bringing a wealth of experience in government, law, healthcare, and public policy to Ratio’s Board.
About Mo Cowan
Senator Cowan currently serves as Chief Legal and External Affairs Officer for Devoted Health, a next-generation, tech-enabled, all-in-one healthcare company. Before joining Devoted Health, Senator Cowan held senior leadership roles at General Electric and served as a partner at a major law firm. He also served as President and CEO of a national government affairs consulting group. Senator Cowan’s distinguished public service career includes his appointment as interim U.S. Senator representing Massachusetts in 2013, as well as senior leadership positions in the administration of Governor Deval Patrick. Senator Cowan is actively involved in various governance and advisory boards, including Massachusetts General Hospital, Duke University, the Edward M. Kennedy Institute for the United States Senate, Stackwell Capital, and Mass General Brigham. Senator Cowan is a graduate of Duke University and Northeastern University School of Law. He holds honorary degrees from Georgetown University’s McDonough School of Business, Bridgewater State College, and Newbury College.
About Ratio Therapeutics
Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio’s proprietary R&D platforms, Trillium and Macropa, enable the development of tunable radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. Ratio, in collaboration with Lantheus and PharmaLogic, is currently conducting a Phase I trial to evaluate the efficacy of a novel fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers in adult healthy volunteers. The company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials this year.
For more information: https://ratiotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.